Novel N-4-piperazinyl-ciprofloxacin-chalcone Hybrids: Synthesis, Physicochemical Properties, Anticancer and Topoisomerase I and II Inhibitory Activity

Overview

Journal Eur J Med Chem

Specialty Chemistry

Date 2013 Oct 5

PMID 24090914

Citations 22

Authors

Mohamed Abdel-Aziz

So-Eun Park

Gamal El-Din A A Abuo-Rahma

Mohamed A Sayed

Youngjoo Kwon

Affiliations

Soon will be listed here.

Abstract

A group of novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids was prepared. One-dose anticancer test results indicated that compounds 3a and 3g exhibited the highest ability to inhibit the proliferation of different cancer cell lines. Compound 3a exhibited a broad-spectrum of anti-tumor activity without pronounced selectivity while compound 3g revealed high selectivity toward the leukemia subpanel with selectivity ratio of 6.71 at GI₅₀ level. Moreover, compounds 3e and 3j have shown remarkable topo II inhibitory activity compared to etoposide at 100 μM and 20 μM concentrations. Compounds 3e and 3j exhibited comparably potent topo I inhibitory activity at 20 μM concentration compared to camptothecin. Compounds 3e and 3j exhibited strong topo II inhibitory activities compared to topo I at 20 μM concentration. Studying of the solubility and partition coefficient revealed higher lipophilicity of the hybrids 3a-j compared to the parent ciprofloxacin.

Citing Articles

From Infection to Tumor: Exploring the Therapeutic Potential of Ciprofloxacin Derivatives as Anticancer Agents.

Hassan H, Hassan R, Elmagzoub R, Al-Emam A, Kossenas K, Abdel-Samea A Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861135 PMC: 11768150. DOI: 10.3390/ph18010072.

In Silico Evaluation of Some Computer-Designed Fluoroquinolone-Glutamic Acid Hybrids as Potential Topoisomerase II Inhibitors with Anti-Cancer Effect.

Oancea O, Gaz S, Marc G, Lungu I, Rusu A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770435 PMC: 11679884. DOI: 10.3390/ph17121593.

Design, synthesis and mechanistic study of N-4-Piperazinyl Butyryl Thiazolidinedione derivatives of ciprofloxacin with Anticancer Activity via Topoisomerase I/II inhibition.

Aziz H, El-Saghier A, Badr M, Elsadek B, Abuo-Rahma G, Shoman M Sci Rep. 2024; 14(1):24101.

PMID: 39406816 PMC: 11480511. DOI: 10.1038/s41598-024-73793-y.

New 6-nitro-4-substituted quinazoline derivatives targeting epidermal growth factor receptor: design, synthesis and anticancer studies.

Farag A, Othman A, El-Ashrey M, Abbas S, Elwaie T Future Med Chem. 2024; 16(19):2025-2041.

PMID: 39230501 PMC: 11485908. DOI: 10.1080/17568919.2024.2389772.

Levofloxacin reposition-based design: synthesis, biological evaluation of new levofloxacin derivatives targeting topoisomerase II beta polymerase as promising anticancer agents, molecular docking, and physicochemical characterization.

Mahmoud Z, Ismail M, Kamel M, Youssef A RSC Adv. 2024; 14(38):28098-28119.

PMID: 39228758 PMC: 11369887. DOI: 10.1039/d4ra03975k.